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The reasons for the increased incidence of de novo anti-human leukocyte antibody (HLA) donor-specific antibodies (DSAs) observed after kidney allograft nephrectomy are not fully understood. One advocated mechanism suggests that at graft loss, DSAs are not detected in the serum because they are fixed on the nonfunctional transplant; removal of the kidney allows DSAs to then appear in the blood circulation. The aim of our study was to compare anti-HLA antibodies present in the serum and in the graft at the time of an allograft nephrectomy. Using solid-phase assays, anti-HLA antibodies were searched for in the sera of 17 kidney transplant patients undergoing allograft nephrectomy. No anti-HLA antibodies were detected in the graft if they were not also detected in the serum. Eleven of the 12 patients who had DSAs detected in their sera also had DSAs detected in the grafts. Epitopic analysis revealed that most anti-HLA antibodies detected in removed grafts were directed against the donor. In summary, our data show that all anti-HLA antibodies that were detected in grafts were also detected in the sera. These intragraft anti-HLA antibodies are mostly directed against the donor at an epitopic level but not always at an antigenic level.
Introduction
An allograft nephrectomy is often required after a kidney allograft fails; however, several studies have shown an increased risk of anti-human leukocyte antibody (HLA) immunization after kidney allograft nephrectomy (1) (2) (3) (4) . In a previous study using the Luminex single-antigen assay (Luminex Corp., Austin, TX), we reported that donor-specific antibodies (DSAs) were detected in 52.4% of patients who had not undergone an allograft nephrectomy versus 81% in those who had (p = 0.02). At the time of the allograft nephrectomy, however, the numbers of patients that had DSAs were similar between groups.
The mechanism leading to the appearance of DSAs after allograft nephrectomy is not fully known. It has been suggested that DSAs are absorbed by the kidney allograft. After nephrectomy, DSAs produced by longlived cells in lymphoid organs may be detectable in the serum compartment at higher concentrations possibly because of the absence of a reservoir for DSA sequestration (5). In only a few studies have DSAs been detected in eluates from allograft nephrectomies obtained from patients in which DSAs were not detected in the sera (6) . In these studies, however, screening for anti-HLA antibodies was done using less sensitive assays than the current single-antigen bead assay.
In the present study, we aimed to characterize anti-HLA antibodies trapped in the failed kidney allograft. We compared anti-HLA antibodies present in the serum and those eluted from the graft at the time of allograft nephrectomy and compared their donor specificities at antigenic and epitopic levels.
Patients and Methods
Between February 2010 and October 2013, 17 patients were included in this study. All patients had experienced graft loss at ≥1 year after transplantation. The allograft nephrectomy was performed at ≥3 mo after graft loss. At our center, the policy is to stop immunosuppression in all patients at graft loss; therefore, at allograft nephrectomy, immunosuppression had been stopped for at least 3 mo.
The indications for an allograft nephrectomy were a history of BK virus nephropathy (3 of 17 patients, 17.6%), requirement of an allograft nephrectomy to enable subsequent transplantation (11 of 17, 64.7%), recurrent pyelonephritis (1 of 17, 5.9%), gross hematuria (1 of 17, 5.9%) or suspicion of cancer (1 of 17, 5.9%). All patients gave their written informed consent to participate in this study, which was approved by Toulouse University's institutional review board.
All patients had anti-HLA antibodies assessed at allograft nephrectomy. In addition, cortical fragments of the kidney allograft were obtained during surgery, frozen in liquid nitrogen and stored at À80°C.
Elution of the kidney allograft specimen
Gamma ELU-Kit II elution kits were used (no. 07861; Immucor, Norcross, GA). Frozen transplant fragments were thawed at room temperature, minced into thin slices, washed with 2 mL of freshly prepared washbuffer solution and centrifuged at 1000g for 5 min. Washing and centrifugation were repeated seven times based on the exponential decrease in optical density (260 nm) of the wash supernatant. The final wash supernatant was tested using a LABScreen Mixed Luminex assay (One Lambda, Canoga Park, CA) to control for efficiency of washing; no anti-HLA antibodies were detected in the final wash supernatant. Screened test results were reported as the normalized background (NBG) ratio for each bead in the assay. An NBG cutoff ratio of >2.2 was considered positive for anti-HLA antibodies, according to the manufacturer's recommendations. The minced slices were incubated with 200 lL of acid-eluting solution for 10 min at room temperature and then centrifuged at 1000g for 5 min. Next, 150 lL of acid elution was neutralized with a buffer solution and analyzed for anti-HLA antibodies.
Immunological analyses
Luminex assays determined the specificity of HLA class I and II IgG antibodies in the recipients' sera (centrifuged at 10 000g for 10 min) using LABScreen single Ag-HLA class I and II detection tests (One Lambda), according to the manufacturer's instructions. The presence and specificity of antibodies were then detected using a LABScan 100 system (One Lambda), and the mean fluorescence (baseline value) for each sample in each bead was evaluated. The baseline value was calculated as follows (MFI indicates mean fluorescent intensity):
ðraw sample MFI -raw negative serum control MFIÞÀ ðnegative-bead raw MFI with sample -negative-bead raw MFI with negative serum controlÞ:
Anti-MHC class I polypeptide-related sequence A (anti-MICA) antibody screening was performed using a LABScreen Mixed kit (One Lambda).
Sera obtained before the nephrectomy were tested with and without dithiothreitol (DTT; 2 lL at 37°C for 15 min; Sigma-Aldrich, St. Louis, MO). MFI data obtained after treatment with DTT were compared with MFIs from sera with noncomplemented elution to avoid variation in MFI values, as has been described by others (7) (8) (9) . A baseline MFI value >1000 was considered positive.
Epitope analyses
We used the HLAMatchmaker program version 2.1 (http://www. epitopes.net/) to determine donor-recipient mismatches at an epitopic level for class I and II HLA, as described previously (3, 10, 11) . Intragraft anti-HLA antibodies were considered epitopic DSAs when they had at least one donor epitope mismatch with the recipient. Four-digit typing was estimated using four-digit converter software. The Cn3D program (National Center for Biotechnology Information, Bethesda, MD) for threedimensional modeling was used to locate reactive epitopes on the HLA molecules.
Pathological analysis of the explanted allograft
The explanted kidney allografts were analyzed using light microscopy (hematoxylin and eosin, Periodic Acid-Schiff reaction and Masson's trichrome staining), and histological lesions were scored using the 2009 Banff classification (12) . C4d staining by immunohistochemistry was also performed. Samples in which C4d staining showed >10% peritubular capillaries were considered positive for C4d deposition. CD34 immunostaining was performed on each explanted graft. Scanning morphometry software (NDP 2.5; Hamamatsu Photonics KK, Hamamatsu City, Japan) allowed calculation of the remaining vascular compartments within the histological section.
Statistical analyses
Clinical data are reported as mean (plus or minus standard deviation) or median (range), as appropriate. Proportions were compared using the Fisher exact test. Quantitative variables were compared using the Wilcoxon test or Student t-test for matched-pair samples. The MannWhitney nonparametric test was used for independent sample comparisons. A p-value of <0.05 was considered statistically significant.
Results
The patients' characteristics are presented in Table 1 .
Detection of anti-HLA antibodies in the serum at allograft nephrectomy At allograft nephrectomy, 14 of the 17 patients had detectable anti-HLA antibodies in their sera: Three patients had only anti-class I antibodies, four had anticlass II antibodies and seven had anti-class I and II antibodies. Among these 14 patients, 12 patients had DSAs, of which two had DSAs directed against only class I HLA antigens, three had DSAs directed against only class II antigens and seven had DSAs directed against class I and II antigens. The data on reactive antibodies are presented in Table 2 .
Detection of anti-HLA antibodies in the allograft Intragraft anti-HLA antibodies were detected in 11 patients (patient numbers 1, 2, 4, 5, 6, 7, 9, 10, 12, 16, and 17) (Table 3) , and DSAs were detectable in both sera and grafts. These DSAs were anti-class I in one patient, anti-class II in three patients and both anti-class I and II in seven patients. The data on reactive antibodies in the sera and the grafts are presented in Table 2 . For anticlass I DSAs, there were 3 AE 1.8 and 3.4 AE 2.1 (p = 0.69) reactive antibodies in the sera and grafts, respectively. For anti-class-II DSAs, there were 5.6 AE 2.7 and 5.3 AE 3.6 (p = 0.94) reactive antibodies in the sera and the grafts, respectively. Comparison of the proportions of reactive antibodies between the serum and the graft showed an 11% increased proportion of anti-class II reactivity in the graft compared with the serum (Figure 1 ).
No anti-HLA antibodies were detected in the grafts of two patients (patients 11 and 13) who had detectable anti-HLA antibodies in their sera (one patient had anticlass I antibodies and the other had anti-class II antibodies) with no DSAs. Another patient (number 15) had a DSA and anti-class I HLA antibodies in the serum; these were not detected in the graft. For these three patients, the numbers of anti-HLA reactions and their MFIs were relatively low (Table 3) .
Patients 3, 8, and 14 had no anti-HLA antibodies detected in their sera or grafts.
Overall, 64.1% of the anti-HLA antibodies detected in the sera were also detected in grafts: 55.3% were anticlass I anti-HLA antibodies and 72.3% were anti-class II anti-HLA antibodies. Overall, 85.2% of DSAs detected in the sera were also detected in grafts: 71.4% were anticlass I DSAs and 93.3% were anti-class II DSAs.
At the time of allograft nephrectomy, six patients had detectable anti-MICA antibodies. Four of these patients also had anti-MICA antibodies detected in grafts. Of note, no anti-class I or II anti-HLA antibodies were detected in the grafts when theses subtypes were not also detected in the sera.
Many reactive antibodies were observed in the grafts: A total of 173 reactive antibodies were directed against class I antigens and 240 reactive antibodies were directed against class II antigens in the 11 patients with a positive elution. Analyzing these reactive antibodies at an allelic level revealed that 15.6% of anti-class I reactivity and 23.3% of anti-class II reactivity were directed against the donor antigens and were considered DSAs. For the remaining reactive antibodies, we analyzed donor specificity at the epitopic level (Tables 4 and 5 ). We converted allelic mismatches to epitopic mismatches using HLAMatchmaker software. An epitopic mismatch was considered a structural difference in amino acids between the donor and recipient HLA alleles. We then analyzed epitopic specificity of positive reactivity found in each patient's graft and compared these epitopic specificities with the donor's epitopes. Anti-HLA reactivity that contained an epitope directed specifically against the donor was considered a DSA.
Analyzing this positive reactivity at an epitopic level revealed that 87.3% of anti-class I reactivity and 79.6% of anti-class II reactivity were directed against the donor epitopes. Of the remaining 12.7% anti-class I reactivity, 45.5% was directed against HLA-Cw antigens; however, the donors' Cw types were unavailable. Similarly, for the remaining 20.4% anti-class II reactivity, 75.5% was directed against DP antigens, although the donors' DP types were unavailable. Patients 2 and 5 had anti-A and anti-B reactive antibodies, respectively, but no epitopic mismatches were found. This can be related to crossreactivity between HLA-A and -B reactivity because they shared common epitopes (bold circled epitope in Table 4 ).
Most of these immunogenic epitopes seemed to be exposed on the HLA molecule surfaces that were accessible to antibodies, as shown in Figure 2 .
Histological analysis of kidney allografts
The pathological analysis of explanted grafts revealed, in particular, the presence of chronic histological lesions (Table 1) . C4d staining was performed after each kidney allograft nephrectomy and was found to be positive in 11 of the 17 patients. Eleven patients had a positive elution for anti-HLA antibodies or DSAs; of these, nine were C4d positive and two were C4d negative. Six patients had a negative elution for anti-HLA antibodies or a DSA; of these, five patients were C4d negative and one patient was C4d positive (p = 0.03) (Figure 3 ).
Concerning CD34 immunostaining, no differences in vascular area were found between grafts with a positive or negative elution for anti-HLA antibodies (p = 0.23) (Figure 3 ).
Discussion
It has been suggested that HLA sensitization can be observed after an early or later allograft nephrectomy.
This can be related to undetected anti-HLA antibodies that become trapped within the kidney (5).
The aim of our study was to compare anti-HLA antibodies present in the serum and those eluted from the graft at the time of an allograft nephrectomy, to assess whether undetected sera anti-HLA antibodies were already present in the kidney at the time of the allograft nephrectomy, and to compare their donor specificity at antigenic and epitopic levels.
Our findings were threefold: (i) No anti-HLA antibodies were detected in any grafts without also being detected in the sera; (ii) nearly all patients who had DSAs detected in sera also had a DSA detected in the graft (11 of 12 patients); and (iii) epitopic analysis revealed that most anti-HLA antibodies detected in the removed kidney were directed against the donor.
At the time of allograft nephrectomy, 14 of the 17 patients had detectable anti-HLA antibodies in the serum, and DSAs were detectable in the failed kidneys of 11 of these patients. C4d staining was positive in nine of these 11 patients with positive DSAs in the graft (82%). Finally, the number of reactions tended to be lower in the graft elution than in the serum. Interestingly, no anti-HLA antibodies were detected in grafts without also being detected in the sera.
Very few studies have assessed the presence of anti-HLA antibodies in the kidney allograft, particularly at the time of an allograft nephrectomy. Heinemann et al reported that explanted kidney allografts harbored anti-HLA antibodies directed against the donor (6). Different IgG isotypes have been detected in explanted kidneys. Martin et al assessed DSAs using flow cytometry on sera and failed allograft kidneys. They found that DSAs were present in the sera of 31.6% of patients that had undergone an allograft nephrectomy but in 70.6% of the eluted kidneys (13) . In another study, Bocrie et al showed that DSAs were present in 58.3% of transplants but in only 16.6% of serum samples (14) . These authors found that 72% of patients with detectable DSAs in transplants also had positive C4d staining. In these two latter studies, the proportions of DSAs detected in graft eluates were much higher than those observed in the sera before the allograft nephrectomies. In our study, however, the results were concordant in the serum and the graft (92%).
The difference between these latter studies and ours is probably related to their use of less sensitive detection assays and a possible prozone effect, which can underdetect sera anti-HLA antibodies before an allograft nephrectomy. Indeed, serum decomplementation seems necessary before comparing MFIs for anti-HLA antibodies between sera and decomplemented elutions. Moreover, these authors did not analyze the impact of the vascular loss associated with renal atrophy at graft loss on antibody elution. One can speculate that the DSAs detected in the graft were the same DSAs present in the serum. We argue that the supernatant that we used in our last washing step could be used as a negative control, thus demonstrated that all nonbound anti-HLA antibodies were removed.
More recently, Bachelet et al compared anti-HLA antibodies in the sera and eluates from needle-core biopsies of grafted kidneys. Only 40.5% of DSAs detected in the sera were also detected in the grafts. This result may have been caused by the small size of the tissue samples (15); however, similar to our results, the number of reactions in grafts was lower than in the sera, and no DSAs were detected in grafts without being also detected in sera.
It is well known that DSAs are produced against specific epitopes on mismatched HLA antigens (11, 16, 17) . Because HLA molecules can share multiple epitopes, anti-HLA antibodies can cross-react with different HLA antigens, suggesting a larger panel of epitopic DSAs than expected in allelic mismatch analysis (18, 19) . In our study, intragraft reactivity at an allelic level showed that %20% were directed against the donor; however, analysis done at an epitopic level showed that >80% were directed again the donor. These proportions may be somewhat underestimated because HLA typing for Cw and DP were missing for some donors. Moreover, we suggest that these epitopic DSAs have an impact on the development of chronic humoral rejection and graft failure, as has been described by others (20, 21) .
The mechanism of HLA sensitization in this setting is still unknown. It has been suggested that the removal of the kidney allows DSAs that were trapped in the kidney to appear in the blood circulation. It has been also proposed that an allograft nephrectomy may cause damage that stimulates the immune system, leading to the appearance of DSAs, as explained by the persistence of donor vascular patches (22) (23) (24) . It has also been suggested that anti-HLA antibodies may expand after an inflammation event, such as surgery (25) . In addition, remaining donor antigenpresenting cells located in lymph nodes can stimulate the immune system after immunosuppression is stopped. In the present study, five patients had undergone a previous transplantation, and only one of these patients had a first failed kidney still in place. We cannot exclude that this previous kidney was not a source of HLA sensitization.
Our study has some limitations. The number of included patients was relatively small, and HLA-Cw and -DP types were missing for some donors.
In conclusion, nearly all DSAs present in sera at the time of an allograft nephrectomy were also present in grafts. Conversely, no anti-HLA antibodies were detected in the Epitopes in bold correspond to immunizer and reactive mismatched epitopes from donors. MM, mismatch. Table 5 : Continued graft without also being detected in the serum. Interestingly, most anti-HLA antibodies detected in the graft were directed against the donor at the epitopic level. 
